Acadia Pharmaceuticals Inc. (ACAD) reported first-quarter 2024 earnings of 10 cents per share, beating the Zacks Consensus Estimate of 4 cents. In the year-ago quarter, the company had incurred a loss of 27 cents per share.The bottom line improved year over year owing to higher product sales.Acadia recorded total revenues of $205.8 million, which missed the Zacks Consensus Estimate of $206.9 million. Acadia’s net product revenues comprise revenues generated from the sale of its two marketed products, Nuplaz ...